Novovax has finished submitting its rolling application to seek regulatory approval of its COVID-19 vaccine to Health Canada, the company said Monday.
It is the first protein-based vaccine candidate of its kind and was created using recombinant nanoparticulate technology from the first strain of SARS-Cov-2..